PAPaul A. Arpino

Paul A. Arpino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul A. Arpino has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of 2 Nomogram-Based Strategies for Dosing Argatroban in Patients With Known or Suspected Heparin-Induced Thrombocytopenia

    by Paul A. Arpino, Adrienne J. Goeller, Anthony Fatalo, Elizabeth M. Van Cott

    No study has compared 2 different dosing strategies for argatroban titration nor has any published nomogram demonstrated improvement in outcomes. This study was conducted to evaluate the effectiveness of 2 argatroban nomograms on reaching therapeutic anticoagulation. Patients treated with argatroban were separated into 2 sliding scale groups, percentage adjustments (PAs) and predefined dose increments (PDIs). The primary outcome was the time to reach a therapeutic activated partial thromboplastin time (aPTT). The average initial dose and dose to achieve a therapeutic aPTT were similar between the groups. There was also no difference in the number of dose changes. The time to reach a therapeutic aPTT was 2 hours shorter in the PDI compared to the PA group, 8 ± 4 hours versus 10 ± 4 hours, P = .015. This study demonstrates a significant time advantage associated with a PDI nomogram compared to a PA nomogram but no difference with respect to the number of rate changes.


  • Open Access

    Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study

    by Russel J Roberts, Jeffrey F Barletta, Jeffrey J Fong, Greg Schumaker, Philip J Kuper, Stella Papadopoulos, Dinesh Yogaratnam, Elise Kendall, Renee Xamplas, Anthony T Gerlach, et al.

    Introduction: While propofol is associated with an infusion syndrome (PRIS) that may cause death, the incidence of PRIS is unknown. Determining the incidence of PRIS and the frequency of PRIS-related clinical manifestations are key steps prior to the completion of any controlled studies investigating PRIS. This prospective, multicenter study sought to determine the incidence of PRIS and PRIS-related clinical manifestations in a large cohort of critically ill adults prescribed propofol. Methods: Critically ill adults from 11 academic medical centers administered an infusion of propofol for [>/=] 24 hours were monitored at baseline and then on a daily basis until propofol was discontinued for the presence of 11 different PRIS-associated clinical manifestations and risk factors derived from 83 published case reports of PRIS. Results: Among 1017 patients [medical (35%), neurosurgical (25%)], PRIS (defined as metabolic acidosis plus cardiac dysfunction and [>/=] 1 of: rhabdomyolysis, hypertriglyceridemia or renal failure occurring after the start of propofol therapy) developed in 11 (1.1%) patients an average of 3 (1-6) [median (range)] days after the start of propofol. While most (91%) of the patients who developed PRIS were receiving a vasopressor (80% initiated after the start of propofol therapy), few received a propofol dose >83 mcg/kg/min (18%) or died (18%). Compared to the 1006 patients who did not develop PRIS, the APACHE II score (25 +/- 6 vs 20 +/- 7, P = 0.01) was greater in patients with PRIS but both the duration of propofol use (P = 0.43) and ICU length of stay (P = 0.82) were similar. Conclusions: Despite using a conservative definition for PRIS, and only considering new-onset PRIS clinical manifestations, the incidence of PRIS slightly exceeds 1%. Future controlled studies focusing on evaluating whether propofol manifests the derangements of critical illness more frequently than other sedatives will need to be large. These studies should also investigate the mechanism(s) and risk factors for PRIS.


  • Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit

    by P. A. Arpino, B. T. Thompson

    Opiates are the mainstay of analgesia in the intensive care unit (ICU). Unfortunately, constipation is a common adverse effect associated with opioid use. Naloxone is a pure opiate antagonist that is frequently utilized in practice for the prophylaxis or treatment of opiate-induced constipation in the ICU. Despite extensive first pass metabolism in the liver there remains the potential for opiate reversal after oral administration. We sought to assess the safety of enteral naloxone in the ICU for the treatment of opiate-induced constipation. Patients who were ordered enteral naloxone while in the ICU were identified through the Pharmacy's computer system. Patients were included in the data analysis if they had received at least one dose of enteral naloxone and had received standing opiates for at least 48 h prior to the initial naloxone dose. Patients were excluded from data analysis if the Richmond agitation-sedation scale (RASS) score was not utilized, they were paralysed or the medical record indicated that extubation was planned within the following 24 h. Data points were recorder at the following times with respect to each naloxone dose administered; time -2, -1, 0, 1, 2 and 4 h. The following data points were collected before and after each naloxone dose; blood pressure, heart rate, respiratory rate, RASS score, pain assessment score (recorded as present or absent), midazolam dose, propofol dose and fentanyl dose. In order to assess for possible opiate reversal the peak fentanyl, propofol and midazolam dose, vital sign value, RASS score and pain score were compared before and after each dose of naloxone. The mean naloxone dose was 3.6 +/- 0.9 mg. There was no significant change in RASS score around the naloxone doses, -2.9 +/- 1.4 before and -2.8 +/- 1.6 after (P = 0.28). There were no significant changes in mean fentanyl, propofol or midazolam dose around naloxone administration. There were also no significant changes in heart rate, blood pressure and respiratory rate or in the presence of pain. These results demonstrate that the administration of enteral naloxone to patients on intravenous opiates in the ICU setting was not associated with changes in sedation score, vital signs, fentanyl dose, midazolam dose or propofol dose.


  • Comparing the Activated Clotting Times Obtained From 2 Point-of-Care Devices in Patients Receiving Unfractionated Heparin During Percutaneous Coronary Intervention

    by Paul A. Arpino, Susan Cronin-Jenkins, Domenic Misiano, Elizabeth Van Cott

    To introduce the Medtronic Plus ACT device (Medtronic, Minneapolis, Minn) into practice, we compared the activated clotting times (ACTs) obtained from the Medtronic Plus ACT device with those obtained from the Hemochron 401 ACT device (International Technidyne Corp, Edison, NJ) in patients undergoing percutaneous coronary intervention. Patients undergoing cardiac catheterization who received unfractionated heparin provided blood at one or more arbitrarily selected time points during their procedure. The ACTs were obtained from the Hemochron 401 using Celite 510 tubes and simultaneously from the Medtronic Plus using either a low-range cartridge (LRC) or high-range cartridge (HRC). Data were divided into 2 groups for analysis based on which cartridge was used in the Medtronic device (ie, LRC or HRC). Linear regression lines and Bland-Altman plots were constructed comparing ACTs from the Hemochron device with those obtained from each Medtronic LRC and HRC groups. The correlation coefficients for both the HRC and LRC regression lines were R2 = 0.576 and R2 = 0.806, respectively. The Bland-Altman plots demonstrated a smaller, but more variable, bias with the HRC compared with the LRC. The ACT obtained during percutaneous coronary intervention in patients receiving unfractionated heparin is dependent on what technology is used. When laboratories introduce new technology to measure ACTs and guide therapy, proper quality assurance should be performed to minimize the risks of anticoagulation.


  • Feasibility of dexmedetomidine in facilitating extubation in the intensive care unit

    by P. A. Arpino, K. Kalafatas, B. T. Thompson

    Spontaneous breathing trials (SBT) and intermittent mandatory ventilation (IMV) are common techniques utilized to expedite the ventilator weaning process. These techniques often require the reduction and/or discontinuation of sedatives and analgesics. Reducing these medications can lead to agitation and the inability to conduct SBTs or weaning by IMV. Adding dexmedetomidine (dex), a potent alpha-2-adrenergic receptor agonist that possesses sedative, anxiolytic and analgesic effects without causing significant respiratory depression, may facilitate extubation in these patients. To assess the feasibility of adding dex to facilitate extubation in a group of difficult-to-extubate patients secondary to agitation. Mechanically ventilated patients who were deemed difficult to wean and extubate secondary to agitation were evaluated for dex therapy. Inclusion criteria were location in an intensive care unit, intubated and mechanically ventilated, required IV sedation, deemed suitable by unit criteria for weaning and extubation within 24 h of dex initiation, previous attempts at weaning sedation and/or analgesia resulted in agitation causing either severe patient ventilator dyssynchrony, prolong need for intubation, or an inability to conduct a successful SBT. Additional inclusion criteria were unsuccessful use of traditional intravenous agents to control agitation. Recommended dex dosing was a bolus of 1 microg/kg followed by an infusion of 0.2-0.7 microg/kg/h. Twenty-five patients were evaluated for dex therapy with 20 meeting the criteria to treat. All had failed prior attempts at weaning. Fourteen of the 20 patients were successfully weaned and extubated and one patient was reintubated within 48 h, giving a 65% success rate. Heart rate trended down after dex initiation in most patients but did not result in the discontinuation of dex in any patient. The addition of dex was associated with minimal changes in mean arterial pressure. Dexmedetomidine was initiated in a group of mechanically ventilated patients who failed previous attempts at weaning and extubation secondary to agitation. After dex initiation, 65% of the patients was successfully extubated. Dexmedetomidine was associated with a reduction in concomitant sedative and analgesic use with minimal adverse effect.


  • Practical Pharmacologic Aspects of Therapeutic Hypothermia After Cardiac Arrest

    by Paul A. Arpino, David M. Greer

    Therapeutic hypothermia has emerged as an effective means of improving neurologic outcomes among cardiac arrest survivors. To achieve optimal results, clinicians must understand and anticipate potential adverse effects of cooling and provide rigorous monitoring and/or pharmacologic interventions as appropriate. Using pharmacotherapy to counter adverse effects of cooling or to treat an intrinsic process under hypothermic conditions requires understanding how hypothermia will influence the clinical effects of the drug, including the drug's pharmacokinetics and pharmacodynamics. The pharmacologic aspects of therapeutic hypothermia in relation to physiology and adverse effects are reviewed.


  • Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin

    by Paul A. Arpino, Zareh Demirjian, Elizabeth M. Van Cott

    Study Objective. To determine the clinical utility of the chromogenic factor X level for conversion from argatroban to warfarin in hospitalized patients. Design. Prospective observational study. Patients. Sixty‐two hospitalized patients with indications for anticoagulation in whom the chromogenic factor X assay was used for conversion from argatroban to warfarin. Setting. University‐affiliated hospital. Intervention. From December 2003–May 2004, data for all patients in whom the chromogenic factor X assay was used for conversion from argatroban to warfarin were screened for inclusion. When the chromogenic factor X level was satisfactory, the clinician discontinued the argatroban and a confirmatory international normalized ratio (INR) was obtained. Measurements and Main Results. To determine the ability of the chromogenic factor X level to predict the INR free of argatroban influence, we calculated the sensitivity and specificity by using a cutoff chromogenic factor X level of 45% or less, or greater than 45%, which corresponded to an INR of 2 or greater, or less than 2, respectively. We constructed a receiver operating characteristic curve to illustrate various cutoff levels of chromogenic factor X. Of 146 patients screened, 62 had data that met criteria for analysis. An average of 6 ± 3 doses of warfarin were administered before the confirmatory coagulation studies were obtained. The average time from the chromogenic factor X measurement to obtainment of confirmatory coagulation studies was 9 ± 4 hours. Use of a chromogenic factor X level of 45% or less to predict an INR of 2 or greater absent of argatroban influence had a sensitivity of 93%, a specificity of 78%, and an accuracy of 89%. The area under the receiver operating characteristic curve was 0.91 (95% confidence interval 0.81–0.99, pConclusion. The chromogenic factor X level is an accurate alternative when converting hospitalized patients from argatroban to warfarin. A chromogenic factor X level of 45% or less is a reliable predictor that the INR will be therapeutic when argatroban therapy is discontinued.


  • Effect of Renal Function on the Pharmacodynamics of Argatroban

    by Paul A Arpino, Robert K Hallisey

    BACKGROUND: Argatroban is a direct thrombin inhibitor used to treat heparin-induced thrombocytopenia (HIT). Argatroban is primarily cleared by hepatic mechanisms, with only small amounts of unchanged drug cleared by the kidneys. OBJECTIVE: To assess the effects of renal function on argatroban dose and activated partial thromboplastin time (aPTT). METHODS: Patients treated with argatroban were identified and prospectively screened. Patients with liver dysfunction were excluded from the analysis. Charts and laboratory data were reviewed daily until a therapeutic aPTT was reached or argatroban was discontinued. Data points collected included age, weight, gender, admitting diagnosis, past medical history, indication for anticoagulation, indication for argatroban, initial dose, goal aPTT, titration instructions, liver function tests, serum creatinine (S cr ), blood urea nitrogen, and estimated creatinine clearance (Cl cr ). RESULTS: A total of 66 patients were evaluated and 44 met criteria for inclusion. Baseline S cr was elevated at 1.5 mg/dL (0.9, 2.3; median 25th, 75th percentile), with an estimated Cl cr 40 mL/min/1.73 m 2 (26, 74). The median dose of argatroban to reach the predefined therapeutic range was 1 μg/kg/min (0.68, 2), with a corresponding aPTT of 60 seconds (54, 66). After univariate analysis, Cl cr significantly predicted the therapeutic dose (coefficient b ± SE 0.019 ± 0.004; r 2 0.35; p < 0.001). Covariates that predicted dose were the presence of HIT (coefficient b ± SE −0.61 ± 0.3; p = 0.045), history of myocardial infarction (coefficient b ± SE −0.74 ± 0.3; p = 0.02), and an indication for anticoagulation of deep-vein thrombosis/pulmonary embolism (coefficient b ± SE 0.69 ± 0.3; p = 0.03). CONCLUSIONS: Estimated Cl cr significantly predicted the dose of argatroban needed to reach a therapeutic aPTT.